A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”
FDA granted accelerated approval for Modeyso (dordaviprone) for the treatment of adult and pediatric patients (1 year of age and older) with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
